Evelo Biosciences' Psoriasis Candidate Shows Reductions In Inflammatory Cytokines


Evelo Biosciences Inc EVLO has announced the results of immunological biomarker analyses from its previously reported Phase 2 trial of orally-dosed EDP1815 in mild and moderate psoriasis.

  • Treatment with EDP1815 led to a statistically significant reduction in the release of cytokines compared to placebo: IL-6 (p=0.0003), IL-8 (p=0.0007), and TNF (p=0.0037). 
  • The effect of EDP1815 was observed by the deep tail of reduced cytokine production on the left of the distribution for each cytokine, absent in the placebo groups. 
  • There was no worsening compared to placebo on the right of the distributions, resulting in the overall significant difference between EDP1815 and placebo.
  • Related: Evelo Biosciences Psoriasis Candidate Shows Benefit In Mid-Stage Study.
  • In addition, skin biopsies of active lesions were taken from a subset of six patients who received EDP1815 and achieved at least a 50% improvement in their Psoriasis Area and Severity Index score.
  • RNAseq analysis showed reductions in transcript levels for psoriasis-relevant cytokines interleukin 23 (IL-23), interleukin 12b (IL-12b), and interleukin 17 (IL-17).
  • Six-month follow-up efficacy and safety data from the Phase 2 trial will be available later this quarter.
  • Price Action: EVLO shares are trading 3.91% higher at $4.52 premarket on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsPenny StocksHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!